Photo from Earle Burgess/LinkedIn
Aug 13, 2024, 19:23
Earle Burgess: For men with metastatic prostate cancer who are taking abiraterone and prednisone
Earle Burgess, Atrium Health Levine Cancer Institute, shared a post on LinkedIn:
“For men with metastatic prostate cancer who are taking abiraterone and prednisone:
Authors: Zhenyu Yang, Yuchao Ni, Diwei Zhao , Yijun Zhang , Jun Wang, Lijuan Jiang, Dong Chen , Zhiming Wu, Yanjun Wang , Liru He , Yanxia Shi, Fangjian Zhou , Hao Zeng, and, Yonghong Li.
Source: Earle Burgess/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 00:19
Nov 14, 2024, 00:02
Nov 13, 2024, 23:57
Nov 13, 2024, 23:54
Nov 13, 2024, 23:48
Nov 13, 2024, 23:46
When your PSA level starts to rise, that indicates the emergence of growing, resistant cancer cells.Did you know that switching prednisone to dexamethasone (but continuing abiraterone) might lead to another PSA response.(This is only appropriate for men who do not have cancer-related symptoms when the PSA starts to rise.)By making this switch, roughly 30% of men will see a PSA response of 50% or greater.For men who respond to this strategy, it might delay the time until your doctor needs to make a more significant change in your treatment plan.Ask your doctor about this if you think it may be appropriate for you.”